CME

Complementary and alternative medicine continues to gain traction in Western medicine as a valuable contributor to managing diverse issues of concern in women's health, especially as related to recurrent urogenital infection/bacterial vaginosis and the many varied symptoms associated with menopause. Join us as Dr. Shulman discusses complementary and alternative medicine in women's health. This interview will focus on the place of certain Lactobacillus strains in the treatment of urogenital infection; and how a non-hormonal phytoestrogen extract can help reduce many symptoms of menopause. Dr. Shulman will also address the safety and efficacy of non-hormonal phytoestrogen use in menopause in comparison with other non-hormonal treatment options.

Optimizing Breast Health: Managing Fibrocystic Breast Changes and Mastalgia

Acute coronary syndromes comprise a family of diagnoses which account for over one million separate hospitalizations annually across the United States. Physicians practicing cardiovascular medicine have numerous choices to make in the care of the ASC patient, with respect to choice and timing of various pharmacotherapies, as well as management strategies. More choices still await as the patient makes their way through the hospitalization, and often across several hand-offs in care. This interview will discuss anti-platelet therapies specifically, but anti-thrombotic regimens in a broader sense, specifically as they relate to the evidence-based, with a focus on minimization, or ideally, elimination in treatment gaps.

The emergence of the 2012 ADA/EASD Patient-centered Care Position Statement and subsequent AACE comprehensive guidance for the management of type 2 diabetes (T2DM) has led many to suggest that diabetes care is now not only more complex for the physician but equally confusing for the patient. Nonetheless, adherence to these evidence-based, patient-centered tenets of care for T2DM can improve patient outcomes. Join us as Drs. Brian McDonough and Vivian Fonseca discuss glycemic goals based on individual patients' needs and the pathophysiology-matched treatment options that help achieve those goals.

Short bowel syndrome, or SBS, is a multi-systemic disorder owing to the loss of a significant amount of small bowel, thus resulting in a severe loss of the absorptive capacity of the small intestine. SBS is characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance on a conventionally accepted, normal diet. This interview will discuss the pathophysiologic changes associated with SBS and the dietary manipulation techniques to achieve the best physiologic and quality of life outcomes for these patients. Also discussed will be parenteral and enteral nutrition as a component of intestinal rehabilitation and long-term follow-up as well as medical and pharmacologic therapy, and surgical interventions.

CME credits: 0.25 Valid until: 11/26/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7222Preterm birth (before 37 weeks gestation) presents an important challenge in today's obstetrics. There are over 26,000 infant deaths each year, and nearly 70% of babies who die before their first birthday were born prematurely. Join us as Dr. Prathima P. Setty discusses preterm birth with Dr. Ashley Roman, Medical Director at NYU-Langone Maternal Fetal Care Center in New York, NY. Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 11/25/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7221Physicians practicing cardiovascular medicine in the clinical, non-invasive and interventional settings are confronted with acute and long-term management of patients with Acute Coronary Syndromes, ACS. Their role in acute care is well defined, but their roles in the longer-term management and maintenance of cardiovascular health is less defined. This interview will discuss anti-platelet therapy and the opportunities and challenges in managing these patients with ACS along their journey. Estimated time to complete activity: 15 minutes

CME credits: 0.50 Valid until: 11/25/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7199There are updated criteria for the diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Join us as Dr. James E. Galvin discusses these changes, along with office-based approaches to improve detection of MCI and AD in conjunction with biomarkers. Estimated time to complete activity: 30 minutes Participate and earn CME with other activities in this series: New Frontiers in Alzheimer's Disease: Updates, Advancements, and Changing the Standard of Care with James E. Galvin, MD Biomarkers in Early Alzheimer's Disease: A New Era? with Barry Rovner, MD Established and Emerging Therapies for Alzheimer's Disease with James E. Galvin, MD

CME credits: 0.50 Valid until: 11/25/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7201Biomarkers are useful in predicting the pathology of Alzheimer's disease (AD), and there are different types of biomarkers that may be utilized. Join us as Dr. Barry W. Rovner discusses the epidemiology, risk factors for, and pathogenesis of AD, and the advantages and disadvantages of biomarkers. Estimated time to complete activity: 30 minutes

CME credits: 0.50 Valid until: 11/25/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7202Join us as Dr. James E. Galvin discusses approaches to treatment of Alzheimer's disease, along with discussion of clinical trials for the prevention and management of AD. Estimated time to complete activity: 30 minutes

CME credits: 0.50 Valid until: 11/20/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7219Autoimmunity may be an adverse outcome of immunotherapy treatments. It is important to understand the intricacies of immune deregulation and autoimmunity, and their relationship to disease management. Join us as Dr. Howard L. Kaufman discusses autoimmunity, immunotherapies, and immune tolerance. Estimated time to complete activity: 30 minutes  

Physicians practicing cardiovascular medicine in the clinical, non-invasive and interventional settings are confronted with acute and long-term management of patients with Acute Coronary Syndromes, ACS. Their role in acute care is well defined, but their roles in the longer-term management and maintenance of cardiovascular health is less defined. This interview will discuss anti-platelet therapy and the opportunities and challenges in managing these patients with ACS along their journey.

CME credits: 0.50 Valid until: 11/19/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7191With recent developments in the use of immunotherapy for patients with cancer, it is important that physicians are aware of the basic concepts of immunology. Join us as Dr. Howard L. Kaufman discusses the basics of the immune system, from defining antigens to talking about T cells, B cells and dendritic cells, as well as explaining the differences between innate and adaptive immunity. Estimated time to complete activity: 30 minutes  

CME credits: 0.50 Valid until: 11/19/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7192It is important to understand not only how the immune system works, but how it can attack cancer. Join us as Dr. Howard L. Kaufman discusses various strategies in harnessing the immune system, the differences between passive and active immunotherapy, and how immune therapies are being combined with other modalities for the treatment of cancer. Estimated time to complete activity: 30 minutes  

CME credits: 0.25 Valid until: 11/19/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=7211The European Society for Medical Oncology held its annual Congress in Madrid, Spain from September 26-30, 2014. This meeting provided updates and advancements in numerous areas of cancer diagnosis and treatment, including immunotherapy for patients with non-small cell lung cancer. Join us as Dr. Matt Birnholz and Dr. Suresh Ramalingam discuss updates in immunotherapy and potential new/emergent treatment options for patients with non-small cell lung cancer. Estimated time to complete activity: 15 minutes